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OBJECTIVES: The objective of this study is to analyze the relationship between
12-month renal function and costs in post-kidney transplant patients from the
Brazilian Public Health System (SUS) perspective. METHODS: Non-interventional,
multicenter, retrospectivemedical chart review of patients that underwent kidney
transplantation. Three years follow-up data on resource use and associated costs
from adults (age18 years-old at time of transplantation), single kidney only trans-
plants from Jan/2004 to Jan/2005 were collected from 7 transplant centers in Bra-
zilian hospitals. Data were censored on graft loss. Estimated glomerular filtration
rates (eGFR) at 12-month post-transplantation were calculated using the abbrevi-
ated Modification of Diet in Renal Disease equation and stratified according to the
National Kidney Foundation K/Kidney Disease Outcomes Quality Initiative renal
function categories. Costs were adjusted to year 2004 at an annual discount rate of
5% and converted to 2010 USD. Case mix group costing approach was used to
determine average cost per day of hospitalization, stratified by cause (surgical or
clinical complication) and type (general ward, ICU). RESULTS: 498 subjects were
eligible for the analysis. Outpatient care resource use and associated costs (exclud-
ing costs with immunosuppressive therapy) did not significantly vary among pa-
tients in different eGFR categories, with average annual costs ranging from 664 and
921USD in the first year, 194 and 245USD in the second and 129 and 165USD in the
third year post-transplantation. However, a trend towards of increasing inpatient
costs (p0.001) and incidence of hospitalization per year with declining of renal
functionwas observed. After 3 years post-transplant, 41%of stage 1 Chronic Kidney
Disease (CKD) and 91% of stage 4 patients were re-admited to the hospital at least
once incurring an estimated average cost of 1,239 and 3,654USD, respectively.
CONCLUSIONS:Renal function,measured by 12-month post-transplant eGFR, is an
important determinant of costs of hospitalization in kidney graft recipients.
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OBJECTIVES: To quantify the cost-effectiveness of overactive bladder (OAB) treat-
ment with fesoterodine (FESO) relative to extended release tolterodine (TER) and
solifenancin (SOL) in Sweden based on recently-available data. METHODS: A 52-
week decision-tree model was developed using data from four 12-week, random-
ized clinical trials and published literature. Patients who did not achieve resolution
of urgency urinary incontinence (UUI) at week 4were titrated to higher doses in the
FESO and SOLmodel arms. TER is only available in one dose and all patients there-
fore remained on TER at week 4 regardless of UUI resolution. The published de-
crease in UUI episodes was used to estimate the proportion of UUI resolution with
SOL. Trial discontinuation data were fit to a Weibull survival model and extrapo-
lated to 52 weeks. Changes in health-related quality of life were assessed using
Overactive Bladder Questionnaire data from two of the trials andwere transformed
into preference-based utility values. Regression analysis determinedthe associa-
tion between trial utilities andmicturition/UUI episodes in order to estimate values
for SOL. Medical costs included antimuscarinic drugs, physician visits, laboratory
tests, incontinence pads and costs of OAB- or incontinence-related comorbidities.
Probabilistic sensitivity analysis was used to determine the impact of uncertainty
in the model inputs on its outcomes. RESULTS: 19.5%, 18.0%, and 16.3% of patients
receiving FESO, TER, and SOL, remained on treatment and were continent after 52
weeks. The respective quality-adjusted life years associated with FESO, TER, and
SOL,were 0.762, 0.756 and 0.752; overall costswere kr16,752, kr16,849, and kr17,047,
indicating that FESO is a lower-cost and more effective treatment option than TER
and SOL. Sensitivity analysis confirmed the superiority of FESO in over 80% of
model simulations. CONCLUSIONS: Results suggest FESO has lower costs and
higher efficacy and thus dominates both TER and SOL in treating OAB with UUI in
Sweden.
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OBJECTIVES:Worldwide prevalence of overactive bladder (OAB) is close to 10% in
adults. The urgent feeling to go to the toilet, frequency of voids and urinary incon-
tinence affects lifestyle and productivity of patients. The aim of this study was to
estimate the cost-effectiveness of tolterodine in the managing of OAB from an
institutional perspective.METHODS: A four-state Markovmodel was performed to
estimate health and economic consequences during a time horizon of one year
(one-month cycles). Effectiveness measures were mean percentage reduction in:
number of voids per day, number of urinary urgency events per day and number of
urinary incontinence events per day. Transition probabilities were obtained from a
meta-analysis employing international published literature. Comparators were
tolterodine (2 mg bid) and tablets of oxybutynin (5 mg tid) as reference treatment.
Resource use was obtained from the Instituto Mexicano del Seguro Social (IMSS)
databases (n377 cases). Costs were extracted from institutional (IMSS) official
sources. Costs included: visits to general practitioners and urologists, hospitaliza-
tion, drugs, medical procedures, laboratory tests, imagenology and adverse events
management. Probabilistic sensitivity analyses were performed employing boot-
strapping techniques. Acceptability curves were constructed. RESULTS: Tolterod-
ine and oxybutynin annual costs per patientwere: US$1,654.55 [95%CI US$1,486.97-
US$1,822.13] and US$1,537.38 [95%CI US$1,389.42-US$1,685.33], respectively
(p0.05). Tolterodine exhibits better outcomes than reference in all effectiveness
measures considered (p0.05). Incremental cost-effectiveness ratios for additional
percentage reduction of: number of voids, events of urinary urgency and events of
urinary incontinencewere: US$1,307.34 [95%CI US$1,268.73-US$1,345.96]; US$1,091.39
[95%CI US$1,059.15-US$1,123.62] and US$ 2,915.31 [95%CI US$2,829.14-US$3,001.42],
respectively. Acceptability curve showed that theprobability of tolterodine being cost-
effective is close tooneatawillingness topayofUS$3,170 (regardingpercent reduction
of number of voids). CONCLUSIONS: Tolterodine is more effective than oxybutynin
with similar treatment costs representing a more efficient alternative in the man-
agement of OAB at the IMSS.
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OBJECTIVES: To evaluate the cost-effectiveness of the early conversion of tacroli-
mus to mTOR inhibitors (mTORi) -sirolimus or everolimus- against continuous
treatment with tacrolimus in patients with renal transplantation in Colombia.
METHODS: A Markov model simulating patient’s natural history with renal trans-
plantation was constructed. The model was designed to predict the incidence of
rejection episodes, associated deaths, adverse events and graft loss. An individual-
level simulation was performed, generating 100,000 patients that started in the
reject’s free stage, using monthly cycles upon death or Colombian life-expectancy
(76 years). The model assessed several risk factors (creatinine levels, rejection ep-
isodes and diabetes) associate to graft loss. The transition probabilities were ex-
tracted from a systematic review of published literature. Direct medical costs were
gathered fromofficial databases (SISMED’s 2010 first semester and tariffsmanuals).
The third party payer’s perspective was used in the analysis. The effectiveness
measure usedwas: life - years gained (LYG). A 5 % discount rate was applied for the
costs and health outcomes. Cost-effectiveness ratio (CER) and incremental cost-
effectiveness ratio (ICER) were estimated. Lastly, deterministic and probabilistic
sensitivity analyses were also performed. RESULTS: Compared to tacrolimus,
sirolimus showed a favorable difference of 0.74 LYG (10.26 vs. 9.52); with a CER of
US$37,302 and US$39,731; respectively. In addition, ICER between the two men-
tioned alternatives resulted in US$6,130. For everolimus no published evidence of
efficacywas found for the evaluated scheme, therefore the effectiveness of everoli-
mus was assumed similar to sirolimus exhibiting an ICER of US$ 70.440 against
tacrolimus. Sensibility analyses modifying this last assumption showed themodel
results are robust. CONCLUSIONS: The study suggests that sirolimus strategy is
cost-effective in Colombia for patients with renal transplantation using the 3 GDP
per capita threshold as recommended by the World Health Organization.
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OBJECTIVES: Few published models comparing sacral nerve neuromodulation
(SNM) with intravesical botulinum toxin-A injections (BTX) for the treatment of
idiopathic overactive bladder (OAB) include comprehensive specifications of clini-
cal pathways and costs.We developed amodel that accurately captures the clinical
and economic realities of SNM and BTX therapies.METHODS: Our Markov model,
which takes the United States Medicare perspective, compares two cohorts of hy-
pothetical patients with idiopathic OAB refractory to conservative care: those ini-
tiatingwith SNM (InterStim®Therapy, Medtronic, Inc. Minneapolis, MN) and those
initiating with BTX (BOTOX®, Allergan, Irvine, CA). Both cohorts are similar and
equally likely to receive either therapy. The time horizon is the SNM neurostimu-
lator battery life (5.5 years). The model accounts for treatment success probabili-
ties, adverse events (AEs), and SNM-related adjustments based on clinical litera-
ture and expert clinical input. Quality-adjusted life-years (QALYs) for persistent
OAB and successful treatment come from National Overactive BLadder Evaluation
(NOBLE) study. Patients not responding successfully to initial therapy discontinue
or switch therapies (patients try each therapy once). Costs (manufacturer pricing
and 2010Medicare payment schedules) and benefits are discounted 3% per annum.
RESULTS: At two years, SNM was more costly ($20,240 vs. $17,069 per patient) and
more effective (1.60 vs. 1.56 QALYs per patient). SNM became less costly at 3 years.
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At 5.5 years, initial SNM therapy was less costly ($23,504 vs. $27,720) and more
effective than initial BTX (4.08 vs. 4.04 QALYs). Probabilistic sensitivity analyses
that varied SNM and BTX success and repeat BTX injection probabilities and utili-
ties, confirmed these results. Repeat injections and differences in AEswere respon-
sible for most of the changing costs over time. CONCLUSIONS: Based on a more
clinically comprehensive design and set of inputs than previousmodels, treatment
with SNM may be more cost-effective than BTX, especially over longer periods of
time.
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OBJECTIVES: Hyperphosphatemia leads to increased hospitalizations and mortal-
ity in End-Stage Renal Disease (ESRD). First-line therapy in Canada consists primar-
ily of calcium carbonate (CC). We determined the incremental cost-effectiveness
ratio (ICER) of the non-calcium phosphate binder lanthanum carbonate (LC) as
second-line therapy, from a Canadian healthcare perspective. METHODS: A
Markov model was developed to determine the cost-effectiveness of second-line
LC after therapy failure on CC, compared with continued CC treatment; or alterna-
tively with second-line Sevelamer (SH). Patient-level data (n380) from a prospec-
tive randomized trial were used for LC and CC drug efficacy. For SH efficacy, an
indirect comparison of eight clinical trials was used to calculate a dose-relativity
between SHand LC of 2.7:1. Costs, quality of life,mortality andhospitalization rates
were based on Canadian data. Univariate and probabilistic sensitivity analyses
were performed. RESULTS: Modelling 1,000 dialysis patients, 378 (37.8%) did not
achieve target serum phosphate (SP) levels (1.78 mmol/L) with first-line CC ther-
apy and were eligible for LC. Of these, 168 (44.4%) responded to LC therapy, result-
ing in 49 life years and 29 Quality-adjusted life years (QALYs) gained. The ICER of
second-line LC treatment comparedwith continuedCC treatmentwasCAN$13,200
($4,600-$22,800) per QALY gained. Results were robust to plausible variations in
model parameters. One-year drug costs per additional responder to second-line LC
therapy were $2,600, compared to $4,300 for first-line LC. The model evaluating
second-line use of LC vs second-line use of SH estimated that LC had similar effi-
cacy but was 16% less expensive than SH. CONCLUSIONS: Second-line treatment
with LC is cost-effective compared to continued therapy with CC; and is less ex-
pensive compared to first-line LC. LC had lower costs compared with SH, due to
lower dose requirements for similar efficacy. These results reinforce current treat-
ment guidelines to treat patients not achieving target SP levels on CC with second-
line LC.
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OBJECTIVES: Cytomegalovirus (CMV) disease can severely impact patient out-
comes and costs associated with kidney transplant. The IMPACT study has shown
that kidney transplant patients significantly benefit from extending valganciclovir
prophylaxis from 100 to 200 days. The objective of this study was to determine the
cost-effectiveness of valganciclovir 200 day prophylaxis compared to 100 days in
kidney transplant patients at high-risk for developing CMV disease. METHODS: A
Markov model was developed to capture time spent by patients in various health
states, which included: CMV, No-CMV, Acute Rejection, Graft Failure, Dialysis and
Death. Results were reported as incremental cost per additional quality adjusted
life-years (QALY) gained, over a 10-year period. Transition probabilities for the first
year were derived from the IMPACT study. Data beyond the first year were derived
from the published literature and baselinemortality rate was determined from the
Canadian Organ Replacement Register. The base case analysis focused on direct
medical costs only from the perspective of the Ministry of Health (MoH). A second
analysis was conducted from the societal perspective. Cost data were obtained
froma variety of sources and reported as 2010 CanadianDollars. A 5%discount rate
was applied to both costs and patient outcomes. Multiple sensitivity analyses were
undertaken to test the robustness of the model. RESULTS: From the MoH perspec-
tive valganciclovir 200 days prophylaxis is cost-effective when compared to 100
days with an incremental cost-utility ratio (ICUR) of $34,818 per additional QALY
gained. The cost-effectiveness is improved from the societal perspective, with an
ICUR of $32,571 per additional QALY gained. Results were robust over a wide range
of sensitivity analyses tested. CONCLUSIONS: Valganciclovir 200 days is a cost-
effective prophylaxis strategy in kidney transplant patients at high-risk of devel-
oping CMV when compared to valganciclovir 100 days.
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OBJECTIVES: The rate and extent of utilization of IV iron in anemic CKD patients
was quantified. Predictors of IV iron and ESAusewere determined. The impact of IV
iron and ESA use was examined separately for total hospital costs and length of
stay (LOS).METHODS: This is a retrospective cohort analysis within the UHC data
warehouse in the period of January 1, 2006, to December 31, 2008. Inclusion criteria
were age  18 years with a primary/secondary diagnosis of CKD. The exposure of
interest was IV iron and ESA therapy, and the outcome was the difference in total
hospital costs and length of stay. A binomial logistic regression using the GEE
methodology was used to identify predictors of IV iron utilization. Propensity
scores were used to control for confounding. A GEE model using gamma distribu-
tion and log link was used to determine the adjusted hospital cost and length of
stay for the IV iron and ESA and ESA alone therapy groups. RESULTS: 82,947 pa-
tients met the study criteria. Of the 82,947 CKD patients on ESA therapy, only 8%
(n  6678) patients were on IV iron supplementation. Age, race, primary payer,
admission status, severity of illness, dialysis status and physician specialty were
identified as strong predictors of IV ironuse. For patients using both IV iron and ESA
(n6678), mean costs were $34,756 compared to $31,404 for ESA users alone
(n76,269). The overall mean LOS for all patients was 9.75 days. For those using IV
iron, the LOS was 10.71 days, and for those only using ESA, the LOS was 9.66 days.
CONCLUSIONS: Our investigation showed significant reduction in ESA doses with
the use of IV iron supplementation, however, the overall prevalence of IV iron
usage was low. Intravenous iron users were associated with a higher total hospital
cost and longer length of stay than ESA users.
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OBJECTIVES: The aim of our study was to construct the conceptual framework of
the impact of ADPKD on patients to support the use or development of a HRQoL
instrument in ADPKD.METHODS: Based on concepts identified from the literature
and ADPKD physicians/researchers from North America, Europe, and Japan, pa-
tients were asked how ADPKD impacts their physical and social functioning, emo-
tions, and urinary symptoms according to a pre-defined moderator guide. Twenty
focus groups (FGs) were conducted across 11 sites: three cities in North America
(n42), six cities in Europe (n64), and two cities in Japan (n11). FGs were mod-
erated by native speakers and overseen onsite by a US-based scientist. A saturation
table was developed to summarize concepts discussed in the FGs; saturation was
achieved once no new concepts were identified. Concepts were identified based on
themes mentioned by 2 participants within a FG. RESULTS: Concepts generated
from the literature and ADPKD physicians/researchers discussions were endorsed
by ADPKD patients. Agreement of concepts between genders across all countries
was observed. Twenty-eight concepts were identified and categorized into: Physi-
cal Impact (impact on work/housework, limited functioning with mild/moderate
exertion, self-care, diminish sex/intimacy, pain/discomfort in extremities/core,
pain affecting work/housework, pain occurring with activity, modifications in life-
style), Emotional Impact (fatigue, depression, anxiety, guilt of passing it to children,
acceptance/self-education), Urinary Concerns (urgency, frequency, nocturia).
Other concepts identified by patients include effect on diet, concern over body
image, thirst, and disruption of social/leisure activities. Fifty-seven percent of
these concepts were identified in the first FG; 100% saturation was achieved in the
fifth FG. CONCLUSIONS: Identified concepts were universally applicable and their
strength is evident by the achievement of complete saturation after 25% of the FGs.
The completion of this conceptual framework using an iterative process provides a
strong basis to develop an ADPKD-specific HRQoL instrument.
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OBJECTIVES: The aim of this study was to characterize Brazilian-specific immuno-
suppressant (IS) treatment patterns among kidney transplant patients.METHODS:
Non-interventional, multicenter, medical chart review of patients undergoing kid-
ney transplant. Five year follow-up data on IS medication use from adult ( 18
years old at time of transplantation), single kidney only transplants from Jan/2004
to Jan/2005 were collected from 7 transplant center in Brazilian hospitals. Patients
were censored on graft loss or loss of follow-up. RESULTS: Data on 498 patients
were included; 51.2%were female, the, average age was 38.913.9 years, and 55.4%
was recipients of kidneys from deceased donors. Of the 498 patients, 61.2% were
treatedwith tacrolimus (TAC)-based IS regimens as the initial calcineurin inhibitor
(CNI), while 38.8%were treatedwith cyclosporine (CyC). CNI switching fromTAC to
CyC occurred in 4.6%, versus 5.6% that switched from CyC to TAC. There was a
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